Comparative neurobiological effects of ibogaine and MK-801 in rats

被引:9
作者
Baumann, MH
Rothman, RB
Ali, SF
机构
[1] NIDA, Intramural Res Program, Medicat Discovery Res Branch, NIH, Baltimore, MD 21224 USA
[2] US FDA, Natl Ctr Toxicol Res, Div Neurotoxicol, Neurochem Lab, Jefferson, AR 72079 USA
关键词
ibogaine; MK-801; dopamine; corticosterone; prolactin; addiction;
D O I
10.1016/S0376-8716(99)00113-1
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Ibogaine is a plant-derived alkaloid with putative 'anti-addictive' properties. Although ibogaine binds to multiple targets in the brain, recent evidence suggests the drug acts as an N-methyl-D-aspartate (NMDA) antagonist similar to MK-801. The purpose of the present study was to compare neurochemical and neuroendocrine effects of ibogaine and MK-801 in vivo. Male rats received either i.p. saline, ibogaine (10 and 100 mg/kg), or MK-801 (0.1 and 1 mg/kg). Groups of rats (N = 6-8/group) were decapitated 30 or 60 min after injection. Brains were harvested for analysis of dopamine (DA) and its metabolites, while trunk blood was collected for analysis of plasma corticosterone and prolactin. Ibogaine produced marked dose-dependent reductions in tissue DA with concurrent increases in the metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). This profile of ibogaine-induced effects on DA metabolism was consistently observed in the cortex, striatum: olfactory tubercle, and hypothalamus. MK-801, on the other hand, did not reduce DA levels in any brain region but did cause modest region-specific elevations in DA metabolites. Ibogaine and MK-801 caused comparable elevations in circulating corticosterone, but only ibogaine increased prolactin. The present findings show that the effects of ibogaine on DA neurotransmission and neuroendocrine secretion are not fully mimicked by MK-801. Thus, the wide spectrum of in vivo actions of ibogaine can probably not be explained simply on the basis of antagonism at NMDA receptors. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 41 条
[31]   INTERACTIONS OF PHENCYCLIDINE RECEPTOR AGONIST MK-801 WITH DOPAMINERGIC SYSTEM - REGIONAL STUDIES IN THE RAT [J].
RAO, TS ;
KIM, HS ;
LEHMANN, J ;
MARTIN, LL ;
WOOD, PL .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (04) :1157-1162
[32]   COMPARISON OF THE BEHAVIORAL-EFFECTS OF IBOGAINE FROM 3 SOURCES - MEDIATION OF DISCRIMINATIVE ACTIVITY [J].
SCHECHTER, MD ;
GORDON, TL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 249 (01) :79-84
[33]   IBOGAINE ANTAGONIZES COCAINE-INDUCED LOCOMOTOR STIMULATION IN MICE [J].
SERSHEN, H ;
HASHIM, A ;
HARSING, L ;
LAJTHA, A .
LIFE SCIENCES, 1992, 50 (15) :1079-1086
[34]  
SHARPE LG, 1990, 1 NEUR, P5
[35]   A PRELIMINARY INVESTIGATION OF IBOGAINE - CASE-REPORTS AND RECOMMENDATIONS FOR FURTHER STUDY [J].
SHEPPARD, SG .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 1994, 11 (04) :379-385
[36]   Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine [J].
Staley, JK ;
Ouyang, Q ;
Pablo, J ;
Hearn, WL ;
Flynn, DD ;
Rothman, RB ;
Rice, KC ;
Mash, DC .
PSYCHOPHARMACOLOGY, 1996, 127 (01) :10-18
[37]   RECEPTOR-BINDING PROFILE SUGGESTS MULTIPLE MECHANISMS OF ACTION ARE RESPONSIBLE FOR IBOGAINES PUTATIVE ANTI-ADDICTIVE ACTIVITY [J].
SWEETNAM, PM ;
LANCASTER, J ;
SNOWMAN, A ;
COLLINS, JL ;
PERSCHKE, S ;
BAUER, C ;
FERKANY, J .
PSYCHOPHARMACOLOGY, 1995, 118 (04) :369-376
[38]   INHIBITION OF MORPHINE-TOLERANCE AND DEPENDENCE BY THE NMDA RECEPTOR ANTAGONIST MK-801 [J].
TRUJILLO, KA ;
AKIL, H .
SCIENCE, 1991, 251 (4989) :85-87
[39]  
VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956
[40]   A PSYCHOMOTOR STIMULANT THEORY OF ADDICTION [J].
WISE, RA ;
BOZARTH, MA .
PSYCHOLOGICAL REVIEW, 1987, 94 (04) :469-492